Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 940 | 47% |
| 2020 | 14 | 845 | 49% |
| 2021 | 17 | 990 | 51% |
| 2022 | 15 | 1,016 | 53% |
| 2023 | 15 | 1,196 | 56% |
| 2024 | 19 | 908 | 58% |
| 2025 from claims | – | 1,406 1,149–1,658 | 59% |
| 2026 forecast | – | 1,499 1,189–1,898 | 59% |
| 2027 forecast | – | 1,577 1,187–2,105 | 59% |
| 2028 forecast | – | 1,658 1,195–2,315 | 60% |
| 2029 forecast | – | 1,744 1,209–2,532 | 60% |
| 2030 forecast | – | 1,833 1,227–2,758 | 61% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 75% of the cases CMS names in Pennsylvania; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 4% inpatient hospital, 69% hospital outpatient, 27% office. The share outside the hospital has moved +27 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~1,500 | ~51 | ~950 | ~500 |
| 2027 · ~1,600 | ~51 | ~950 | ~570 |
| 2028 · ~1,700 | ~53 | ~980 | ~620 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 38% (27% in 2025), hospital outpatient about 59% (69% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,661+10%/yr | +10%/yr | 0.9 | 48% | 3,360 in 2030+12%/yr |
| Massachusetts | 12 | 677+16%/yr | +16%/yr | 0.7 | 46% | 1,170 in 2030+9.5%/yr |
| New Jersey | 4 | 287+1%/yr | +1%/yr | 0.3 | 22% | 820 in 2030+19%/yr |
| Connecticut | 3 | 119−5.9%/yr | −5.9%/yr | 0.4 | 0% | 170 in 2030+6.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 180 | 9,675−1.1%/yr | −1.1%/yr | 7.60.9× | 8% | 10,100 in 2030+0.8%/yr |
| Tumor ablation | 3 | 418+1.3%/yr | +1.3%/yr | 0.31.2× | 0% | 330 in 2030−3.7%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Exact Sciences leads with 44% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 19 companies reported engagement with Pennsylvania’s surgeons worth $362K in consulting, speaking, meals and travel tied to these products, about $19K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.